Noble Biomaterials develops, manufactures and markets advanced antimicrobial technologies, including its X-STATIC® system for odor elimination and bacterial management. The company supplies odor-elimination solutions to sports apparel companies and bacterial management systems to global healthcare brands. It has more than 200 global licensees across medical, defense, industrial and consumer markets. Noble maintains offices in Europe, Asia and South America. Led by CEO Jeff Keane, the company focuses on commercializing antimicrobial and wound-management products and protecting its technology through intellectual property efforts. The recent financing is intended to support expanded growth initiatives and strengthen the company’s intellectual property management expertise.

Total raised

$8M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2012